Clinical trials: STI
HIV Infection
Study to Evaluate the Safety of Griffithsin in a Carrageenan Gel in Healthy Women
This is a two-part study. The first part is a single-dose open label design. The second part employs a multiple dose, randomized, placebo controlled study design.
- Trial name
- NCT02875119
- Testing
- Griffithsin Gel
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Population Council
HIV Infections
Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir
The main purpose of this study is to examine the effect of tipranavir combined with ritonavir, medications for the treatment of HIV-infection, on buprenorphine/naloxone (BUP) in people who have been receiving the same dose of…
- Trial name
- BUTI (NCT00486330)
- Testing
- Buprenorphine, Tipranavir and ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Yale University
HIV Infections
PrEP2Prevent An Online PrEP Navigation and Activation Intervention
The goal of this clinical trial entitled, PrEP2Prevent: An Online PrEP Navigation and Activation Intervention for YMSM, is to develop and test a method for supporting access to an HIV prevention medication called Pre-Exposure…
- Trial name
- P2P (NCT05281393)
- Testing
- PrEPresent
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Los Angeles
Human Papillomavirus Infection
A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)
This study will evaluate the tolerability and immunogenicity of administration of the first dose of V503 at the same time as Menactra™ and Adacel™ versus administration of V503 one month prior to administration of Menactra™ and…
- Trial name
- NCT00988884
- Testing
- V503, Comparator: Menactra™ (Concomitant), Comparator: Adacel™ (Concomitant)
- Volunteers
- 1,241 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Simplex
A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
The purpose of this first-time-in-human (FTiH) study is to evaluate the reactogenicity, safety, immune response, and efficacy of an investigational herpes simplex virus (HSV)-targeted immunotherapy (TI).
- Trial name
- NCT05298254
- Testing
- Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3
- Where
- 30 sites in United States, Australia and 6 more
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hiv
Enhancing PrEP Outcomes Among Kenyan Adolescent Girls and Young Women With a Novel Pharmacy-based PrEP Delivery Platform
The investigators will conduct a cluster RCT in Kisumu, Kenya to determine the effect of nurse-navigators on PrEP initiation, persistence, and adherence among AGYW seeking contraception within a pharmacy-based PrEP delivery…
- Trial name
- NCT05467306
- Testing
- Nurse-Navigator Enhanced PrEP Support
- Where
- Kenya
- Volunteers
- 1,900 people, healthy volunteers welcome
- Sponsor
- University of Washington
HPV, Human Papilloma Virus
A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV
There are very little data on human papillomavirus (HPV) vaccination among the 18 million women living with HIV (WLWH) globally, who constitute a population most vulnerable to HPV and the resultant cervical cancer.
- Conditions
- HPV, Human Papilloma Virus, Human Immunodeficiency Virus
- Trial name
- NOVA-HIV (NCT05495906)
- Testing
- Nonavalent HPV vaccine
- Where
- 10 sites in Canada
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Healthy Volunteers
Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects
This will be an open-label, fixed-sequence, multiple dose crossover study in 14 healthy male and/or female subjects, to estimate the effect of steady state lersivirine on the steady state pharmacokinetics of abacavir/lamivudine.
- Trial name
- NCT01220232
- Testing
- Abacavir/Lamivudine, Lersivirine
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
HIV Infections
Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144
The purpose of this study is to assess safety and tolerability of late boost regimens of AIDSVAX B/E alone, ALVAC-HIV alone, or ALVAC-HIV/AIDSVAX B/E combination in HIV-uninfected participants from RV 144.
- Trial name
- NCT01435135
- Testing
- ALVAC-HIV, AIDSVAX B/E
- Where
- 2 sites in Thailand
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
HIV/AIDS
Swaziland HIV Incidence Measurement Survey 2
The second Swaziland HIV Incidence Measurement Survey (SHIMS 2, 2016), is a population based HIV Impact Assessment (PHIA) that will assess the prevalence of key human immunodeficiency virus (HIV)-related health indicators.
- Trial name
- SHIMS2 (NCT04117984)
- Where
- Eswatini
- Volunteers
- 15,429 people, healthy volunteers welcome
- Sponsor
- Columbia University
Sexually Transmitted Infections
Sexually Transmitted Infections Among African American Women Who Have Sex With Women
The purpose of this study is to determine rates of sexually transmitted infections (STIs) among African American women who have sex with women (AAWSW).
- Trial name
- WSHP (NCT01546714)
- Where
- 2 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Infections, Papillomavirus
Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This study will further evaluate induction of immune memory and anamnestic responses in women who previously took…
- Trial name
- NCT00546078
- Testing
- Cervarix™
- Where
- 17 sites in United States, Canada
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections, Viral Hepatitis B
Sexual and Reproductive Health (Including PrEP and HBV) for Female Sex Workers in Côte d'Ivoire
The PRINCESSE study will implement a comprehensive package of services in sexual and reproductive health for female sex workers in the region of San Pedro in Cote d'Ivoire, including screening, prevention and treatment for HIV…
- Conditions
- HIV Infections, Viral Hepatitis B, Sexually Transmitted Diseases, Contraception
- Trial name
- ANRS 12381 (NCT03985085)
- Testing
- Comprehensive package of sexual and reproductive health services
- Where
- Côte d’Ivoire
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV
This is a multicenter, open-label, non-randomized, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of CH505M5 N197D mRNA-gp160 and CH505 TF mRNA-gp160.
- Trial name
- NCT06557785
- Testing
- CH505M5 N197D mRNA-gp160, CH505 TF mRNA-gp160
- Where
- 7 sites in United States, Thailand
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS
Using CBPR to Reduce HIV Risk Among Immigrant Latino MSM
The intervention is based on social cognitive theory and theory of empowerment education and was developed using community-based participatory research (CBPR).
- Trial name
- HOLA (NCT03276338)
- Testing
- HOLA
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
HIV Infections
Evaluating the Safety of and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults in Uganda
The RV 156A clinical trial is evaluating an experimental HIV vaccine in people who are not infected with HIV. Participants in that study are randomly assigned to receive either the HIV vaccine or placebo.
- Trial name
- NCT01549509
- Testing
- VRC-HIVADV014-00-VP Vaccine
- Where
- Uganda
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, HIV Seronegativity
Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa
The main goal of this study is to find out how the immune system responds to a specific type of HIV infection, known as C HIV-1, in order to develop a vaccine against this type of infection.
- Trial name
- NCT00006298
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Sexually Transmitted Diseases
Maintaining HIV Prevention Gains in Female Adolescents
In this study, an intervention is tested that is designed to reduced risky sexual behaviors in adolescent females. Study design: randomized, controlled study participants: 640 girls aged 15-19 years old length of follow-up: 1…
- Trial name
- NCT00161343
- Testing
- Health Improvement Project for Teens on HIV Prevention
- Where
- United States
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- University of Rochester
HIV Infection, Tuberculosis Infection
Micro RNA as Prediction and/or Prognostic Markers of IRIS in TB-HIV Co-infected Patients
The role of miRNAs in HIV disease is yet to be completely defined. Host miRNAs target certain HIV genes, thus can affect HIV replication and participate in viral control.
- Trial name
- miRNA (NCT03941210)
- Testing
- Detection of molecular Biomarkers
- Where
- Cambodia
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection, Sexually Transmitted Infection
Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy
Individual-Level Randomized Controlled Trial of an Integrated Strategy of HIV pre-exposure prophylaxis (PrEP) and sexually transmitted infection (STI) post-exposure prophylaxis (PEP) for Young Men
- Trial name
- NCT07658976
- Testing
- HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA, STI PEP - Doxycycline as Doxy-PEP, 3P mHealth package
- Where
- 5 sites in United States, Argentina and 2 more
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- HIV Prevention Trials Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.